🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

XXII XXII

Company Profile ↓
$1.72
-99.66% 1Y
Mkt Cap$43.89K
P/B0.01
52W High$594.00
52W Low$1.72
Book Value$617.50
EPS (TTM)$-1,057.40

Company Overview

XXII (XXII) is a publicly traded company listed on with a market capitalization of $43.89K. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 42.4% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Recent Developments

  • Dec 2025 Revenue of $7.05M (-40.7% YoY); net profit $-5.05M.
  • Trailing 12 Months Year-on-year growth — revenue -40.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 42.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:42.44%
1 Year:-40.65%

Stock Price Performance

1 Year:-99.66%
6 Months:-97.64%
3 Months:-70.03%
1 Month:-58.25%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$1.72 $594.00
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)22.28 · Oversold
Price Performance
1M-58.25%
3M-70.03%
6M-97.64%
1Y-99.66%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 42.4% over 5 years.

CONS

  • Trading 99.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 22 suggests oversold conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.00
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$617.50
Price to Book
0.01
P/S
0.02
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
42.44%
Profit 5Y
-
Revenue (YoY)
-40.65%
Earnings (YoY)
-

Profitability & Returns

ROCE
-57.80%
ROE
-32.07%
ROA
-18.70%
Profit Margin
-71.70%
Op Margin
-
Gross Margin
-44.50%
EPS (Latest Qtr)
$-361.60
EPS (TTM)
$-1,057.40

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
1.83
Current Ratio
2.42
Debt
$1.48M
Total Assets
$30.31M
Current Assets
$21.07M
Working Capital
$10.36M

Ownership

Promoter Holding
15.90%
Chg in Prom Hold
15.90%
FII / Inst Holding
9.31%
Chg in FII Hold
4.00%

Financial Snapshot

Enterprise Value
$43.89K
Total Revenue (TTM)
$7.05M
EBITDA
$-10.53M
Free Cash Flow
$-8.60M
Operating Cash Flow
$-7.72M
Shares Outstanding
25.52K
Gross Margin
-44.50%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------6.12M6.91M6.26M7.13M6.29M5.82M6.46M7.26M7.06M6.43M7.31M7.31M7.96M7.81M8.37M6.81M9.04M9.97M11.54M9.95M8.93M8.05M7.87M7.36M6.47M7.95M5.95M-2.27M2.23M1.50M1.05M1.29M
Cost of Revenue -----------------------------------2.88M2.86M2.56M1.88M1.93M
Gross Profit -140.91K-184.62K-227.81K-273.90K-165.06K-340.37K71.41K71.58K161.71K150.95K514.75K-103.00K-86.30K-21.07K224.73K287.00K--------------------609.00K-635.00K-1.06M-834.00K-636.00K
Operating Expenses -----------------------------------1.96M2.35M2.15M1.82M2.40M
Operating Income -2.83M-2.60M-2.73M-2.97M-3.28M-3.27M-3.77M-4.97M-7.04M-6.21M-5.80M-5.38M-5.03M-7.61M-5.55M-4.14M-4.75M-4.04M-6.25M-5.17M-6.64M-7.57M--8.15M-10.48M-15.27M--10.40M-12.04M-8.25M--4.43M-2.05M-3.38M--2.57M-2.98M-3.21M-2.65M-3.04M
EBITDA ------------------------------------2.42M-2.67M-2.92M-2.51M-2.76M
Interest Expense -----------------------------------558.00K351.00K534.00K12.00K11.00K
Pretax Income ------------------------------------3.27M-3.33M-3.76M-2.78M-3.02M
Tax Provision -----------------------------------0-34.00K06.00K0
Net Income -2.90M-2.68M-2.75M-2.62M-3.36M-3.32M-3.74M1.39M-6.74M6.30M-8.92M-2.07M-8.04M-10.24M-6.20M-4.03M-5.06M-4.22M-6.41M-13.96M-9.44M-4.17M-5.03M-8.92M-11.50M-13.10M-8.92M-18.18M-20.54M-72.72M--5.74M-1.11M-3.76M--4.33M-3.41M5.49M-2.81M-3.26M
Diluted EPS ----0.03--0.03-0.01-0.050.04-0.07-0.02--0.08------0.09-0.06-0.03-0.03-0.05-0.95-0.94-0.05-21.49-23.81-60.75--395.07-593.72-1,760.26--10,929.29-2,229.71-84.00--361.60
R&D Expense 509.93K691.97K-550.85K813.29K784.59K-2.52M4.78M4.01M-2.45M1.99M1.99M-960.00K----903.00K1.03M-1.14M1.90M1.32M-730.00K799.00K623.00K-425.00K250.00K240.00K-162.00K227.00K193.00K-285.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 49.78K1.01M18.77K7.28M528.99K8.52M12.28M16.60M26.43M25.83M28.11M-40.50M16.20M11.88M7.05M
Cost of Revenue ------------38.65M24.89M14.28M10.19M
Gross Profit ---49.19K6.82M30.55K-580.56K-429.70K-707.91K898.99K14.46K--1.85M-8.70M-2.40M-3.14M
Operating Expenses ------------35.81M33.71M11.42M8.28M
Operating Income -1.10M-3.76M-3.24M1.81M-11.77M-12.04M-11.39M-13.30M-24.02M-23.57M-19.18M--33.96M-42.40M-13.82M-11.42M
EBITDA -------------32.89M-40.41M-12.11M-10.53M
Interest Expense ------------55.00K9.37M2.09M1.46M
Pretax Income -------------36.53M-54.64M-15.46M-13.14M
Tax Provision ------------21.00K47.00K30.00K-28.00K
Net Income -1.42M-1.35M-6.74M-26.15M-15.60M-11.03M-11.58M-13.03M-7.97M-26.56M-19.71M--59.80M-140.78M-15.16M-5.05M
Diluted EPS --0.05-0.22-0.60------0.21-0.14--3,147,421.05-75,383,500.00-242,542.86-1,057.40
R&D Expense 363.78K2.10M729.23K744.23K1.22M1.57M2.34M3.37M14.99M8.06M-3.91M3.58M2.64M1.13M688.00K

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -2.80M2.39M2.64M12.29M21.95M18.37M27.64M79.74M77.30M68.95M51.69M-114.65M27.50M21.67M27.02M
Current Assets -------------44.60M16.28M11.52M17.63M
Cash & Equivalents ----5.83M6.40M3.76M13.47M3.66M604.92K485.11K--2.21M2.06M4.42M7.15M
Inventory -------------7.27M4.35M2.02M4.33M
Receivables -------------1.36M1.67M1.70M3.59M
Total Liabilities -4.89M3.60M8.78M4.76M6.73M6.64M3.31M4.31M6.02M6.90M7.58M-18.68M35.91M17.66M11.27M
Current Liabilities -4.82M2.87M4.60M984.33K2.67M3.24M3.25M4.31M5.17M5.78M7.34M-13.02M25.03M9.96M7.27M
Long Term Debt -------------3.00M8.06M5.17M504.00K
Total Debt -------------1.65M16.38M8.62M1.48M
Total Equity -1.80M-2.09M-1.21M-6.13M7.52M15.22M11.73M24.33M75.42M71.28M62.05M44.11M-95.97M-8.41M4.01M15.76M
Shares Outstanding -------------19210525.52K

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -909.94K-3.45M-1.76M3.86M--7.32M-9.89M-12.07M-17.84M-14.59M-15.62M--51.71M-54.99M-14.35M-7.72M
Investing Cash Flow -108.12K-607.30K-162.77K-3.74M--450.66K-553.77K-60.59M15.14M4.55M16.47M-22.58M16.82M-139.00K-505.00K
Financing Cash Flow 1.02M4.31M1.68M5.72M-5.13M20.15M62.85M-355.00K9.92M-304.00K-30.82M37.21M16.85M10.96M
Capital Expenditure ----457.70K-0-0----527.00K-54.00K--4.43M-5.62M-161.00K-875.00K
Free Cash Flow ---3.40M--7.32M----15.12M-15.68M--56.14M-60.60M-14.51M-8.60M
Net Change in Cash ------------1.68M-962.00K2.36M2.73M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---262.0%93.7%5.8%-6.8%-3.5%-4.3%3.4%0.1%--4.6%-53.7%-20.2%-44.5%
Operating Margin % -2,204.0%-371.0%-17,279.1%24.9%-2,224.5%-141.3%-92.7%-80.1%-90.9%-91.2%-68.2%--83.9%-261.8%-116.3%-162.0%
Net Margin % -2,859.6%-133.8%-35,873.7%-359.3%-2,948.1%-129.5%-94.3%-78.5%-30.1%-102.8%-70.1%--147.7%-869.2%-127.7%-71.7%
ROE % 68.2%111.7%109.9%-347.6%-102.5%-94.1%-47.6%-17.3%-11.2%-42.8%-44.7%--62.3%1,673.9%-378.0%-32.1%
ROCE % 54.2%774.1%165.7%16.0%-61.0%-79.6%-46.7%-17.6%-33.3%-37.3%-43.3%--33.4%-1,717.5%-118.0%-57.8%

Shareholding Pattern

Insiders
15.90%
Institutions
9.31%
Public Float
11.08%

Top Institutional Holders

#Holder% HeldSharesValue
1 Anson Funds Management LP 6.69% 34.56K $108.19K
2 UBS Group AG 0.62% 3.21K $10.04K
3 Barclays Plc 0.03% 164 $513
4 Farther Finance Advisors, Llc - 5 $15
5 IFP Advisors, Inc - 2 $6
6 Integrated Wealth Concepts LLC - 2 $6
7 Truvestments Capital, LLC - 2 $6
8 Morgan Stanley - 7 $21
9 Steward Partners Investment Advisory, LLC - 2 $6
10 Osaic Holdings Inc. - 8 $25

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XXII

Yahoo Finance ue, 01 Sep 2026

22nd Century CEO & Chairman Larry Firestone: Improved Gross Margin, ~5,000 Retail Outlets and >$50B Market Opportunity Highlight Mid-Year Stockholder Letter

VLN® Category Leader Accelerates 2H 2026 Growth Phase as Same-Store Sales Climb 22nd Century Accelerates 2H 2026 Commercial Execution MOCKSVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the leader i…

Yahoo Finance ue, 18 Aug 2026

22nd Century Group to Participate in the HC Wainwright Conference on September 15, 2026

MOCKSVILLE, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addicti…

Yahoo Finance hu, 13 Aug 2026

22nd Century Group Inc (XXII) (Q2 2026) Earnings Call Highlights: Strategic Shift Toward ...

Company expands Pinnacle VLN distribution to nearly 150 stores in Metro New York while navigating transition away from low-margin contract manufacturing.

Yahoo Finance hu, 13 Aug 2026

22nd Century Group Reports Second Quarter 2026 Financial Results

Advances VLN® Commercialization Through Expanded Retail Support and Brand-Building Initiatives MOCKSVILLE, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the leader in low-nicotine tobacco, low-nicotine cig…

Yahoo Finance hu, 16 Jul 2026

22nd Century Group (Nasdaq: XXII) Appoints Katherine Rouse-Bailey as Vice President of Marketing

XXII investing in expanded marketing initiatives to drive VLN® brand awareness and growth MOCKSVILLE, N.C., July 16, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company focused on reducing the harms …

Yahoo Finance hu, 21 May 2026

22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes

Initial 60-Store California Entry Extends XXII’s Reduced-Nicotine Rollout Into One of the Nation’s Largest and Most Influential Tobacco Markets, With a Pathway to Broader Expansion MOCKSVILLE, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- 22nd Cen…

XXII — Frequently Asked Questions

What is the current share price of XXII?

As of 2026-09-16 18:39 PDT, XXII trades at $1.72 on NASDAQ/NYSE. Its 52-week range is $1.72 to $594.00.

What is the market capitalisation of XXII?

XXII has a market capitalisation of $43.89K on NASDAQ/NYSE.

What is the return on equity (ROE) of XXII?

XXII has a return on equity (ROE) of -32.07%. Its return on capital employed (ROCE) is -57.80%.

Is XXII a good stock to buy?

This page provides a data-driven analysis of XXII, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space